SCHEMBL4259528

SCHEMBL4259528

CC(C)(C)OC(=O)NCC1CCN(c2ccc(N)c(F)c2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 1/20 0.49
ACACB O00763 6/20 0.47
ACACA Q13085 6/20 0.47
NAMPT P43490 1/20 0.46
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45
SKP2 Q13309 1/20 0.45
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.43
ALOX15 P16050 2/20 0.43
MAPK1 P28482 2/20 0.43
MCL1 Q07820 3/20 0.43
KDM4E B2RXH2 2/20 0.43
USP2 O75604 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259523 1.00 SUV39H2 (0.49) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL4261292 0.84 SUV39H2 (0.46) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL4261290 0.84 SUV39H2 (0.46) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL1749371 0.84 MAPT (0.44) ALDH1A1MAPTALOX15MAPK1MCL1
SCHEMBL1749373 0.84 MAPT (0.44) ALDH1A1MAPTALOX15MAPK1MCL1
SCHEMBL4288052 0.82 ACACB (0.47) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL4288054 0.82 ACACB (0.47) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL15728295 0.81 TRPA1 (0.54) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL10230218 0.80 CKS1B (0.59) SUV39H2ACACBACACANAMPTCKS1B
SCHEMBL10230212 0.80 CKS1B (0.59) SUV39H2ACACBACACANAMPTCKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 US disclosed
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-03-26 US disclosed
EP-1986646-A1 NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS Sanofi-Aventis (FR) 2008-11-05 EP disclosed
WO-2007093363-A1 NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082339-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MCHR1, MPI, TPMT SUV39H2 2750/4885ACACB 4014/4885ACACA 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.